Oral DMSO therapy in 3 patients with lipoidproteinosis. Results of long-term therapy

Lipoid proteinosis is a rare autosomal recessive disorder with a chronic, benign course. There is no generally accepted systemic therapy apart from the experimental oral use of dimethyl sulphoxide (DMSO) and etretinate in two single cases. We treated two sisters and an unrelated man with lipoid prot...

Full description

Saved in:

Bibliographic Details
Published in:	Hautarzt Vol. 48; no. 7; pp. 477 - 481
Main Authors:	Ozkaya-Bayazit, E, Ozarmağan, G, Baykal, C, Uluğ, T
Format:	Journal Article
Language:	German
Published:	Germany 01-07-1997
Subjects:	Administration, Oral Adolescent Adult Chromosome Aberrations - genetics Chromosome Disorders Dimethyl Sulfoxide - administration & dosage Female Follow-Up Studies Genes, Recessive Humans Lipoid Proteinosis of Urbach and Wiethe - drug therapy Lipoid Proteinosis of Urbach and Wiethe - genetics Long-Term Care Male Treatment Failure
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Lipoid proteinosis is a rare autosomal recessive disorder with a chronic, benign course. There is no generally accepted systemic therapy apart from the experimental oral use of dimethyl sulphoxide (DMSO) and etretinate in two single cases. We treated two sisters and an unrelated man with lipoid proteinosis with longterm oral DMSO (60 mg/kg/d). At the end of an average treatment time of 3 years, DMSO was withdrawn because it produced no beneficial effects with regard to their skin, mucosal lesions or hoarseness. Additionally, one patient showed progression of her disease with worsening hoarseness and onset of dyspnea, requiring surgical removal of vocal cord infiltrates. Three patients with lipoid proteinosis failed to show any beneficial response to long term treatment with DMSO.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Report-3 ObjectType-Case Study-4
ISSN:	0017-8470